RFP ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
338進行性家族性肝内胆汁うっ滞症1

338. 進行性家族性肝内胆汁うっ滞症


臨床試験数 : 60 薬物数 : 26 - (DrugBank : 6) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 2
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-UMIN000017823
2013/07/1705/06/2015A study to assess the safety and efficacy of rifampicin for progressive familial intrahepatic cholestasis (PFIC) and benign recurrent intrahepatic cholestasis (BRIC)A study to assess the safety and efficacy of rifampicin for progressive familial intrahepatic cholestasis (PFIC) and benign recurrent intrahepatic cholestasis (BRIC) - A study to assess the safety and efficacy of rifampicin for progressive familial intrahepatic cholestasis (PFIC) and benign recurrent intrahepatic cholestasis (BRIC) Progressive familial intrahepatic cholestasisBenign recurrent intrahepatic cholestasisRifampicin (RFP, 10 mg/kg/day) are given for 4-8 weeks.
When RFP is effective against cholestasis, RFP will be tapered 2.5mg/kg per a week and withdrawn after 4 weeks.
When bilirubin level does not decrease or the continuation of RFP is difficult for some side effects, RFP will be withdrawn.
Department of Pediatrics, Graduate School of Medical Sciences, Kyushu UniversityNULLComplete: follow-up completeNot applicableNot applicableMale and Female3Not selectedJapan